Zhu is the chairman of Sichuan Biokin Pharmaceutical, a producer of anesthetics, cardiovascular drugs and Chinese medicine. The Chengdu, China-based company had revenue of 5.8 billion yuan ($808 million) in 2024 and began trading on the Shanghai exchange in January 2023. It operates in the US as SystImmune.
The majority of Zhu's fortune is derived from his stake in Sichuan Biokin Pharmaceutical, a Chengdu, China-based producer of pharmaceuticals and Chinese medicines. It reported revenue of 5.8 billion yuan ($808 million) in 2024.
Zhu owns 72% of the company directly, according to the company's 2025 third-quarter report. Zhu's younger brother Zhu Xi and younger sister Zhu Ying also own stakes in the company of less than 1%. The siblings' stakes are not credited to Zhu Yi in this analysis.
Zhang Suya, a spokesperson for Sichuan Biokin Pharmaceutical, didn't respond to a request for comment on the net worth calculation.
Zhu was born in December 1963 in Nanchong, a city in the northeast of Sichuan province. He studied radio engineering in Sichuan University and then a postgraduate degree in biophysics in Fudan University. He also obtained a doctoral degree in finance from Sichuan University.
He was a lecturer in the West China University of Medical Sciences, since renamed West China Medical Center of Sichuan University, from 1987 to 1990. He became the director of the university's subsidiary medical factory in 1991.
Zhu was later laid off from the factory. He switched to the property sector in Beihai, a city in the Guangxi province, where he gained his first fortune. He continued to invest in construction material businesses when he returned to Sichuan in 1994.
In 1996, Zhu returned to the medical industry and founded Baili Pharmaceutical, the predecessor company of Sichuan Biokin Pharmaceutical. Sichuan Biokin began trading on the Shanghai stock exchange in January 2023.